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Gatekeepers of pancreas: TEAD and YAP
Santiago A. Rodríguez-Seguí, José Bessa
The pancreas hosts some of the most debilitating 
and deadly diseases, including pancreatic cancer and 
diabetes mellitus. In autoimmune diabetes, for example, 
there is a massive destruction of the insulin producing 
cells of the pancreas. Pancreatic developmental defects 
can also result in a deficit of this cell type. To revert 
these important pancreatic diseases, researchers are 
currently trying to artificially generate insulin producing 
beta-cells for implantation and, in this way, suppress 
insulin administration [1]. However, to derive cells that 
function properly it is necessary to understand in depth 
the instructions that our body uses to produce them during 
fetal development. On the other hand, regarding pancreatic 
cancer, it is known that tumor cells very often recover 
characteristics similar to those of embryonic cells [2]. 
These are clear examples of the relevance to understand 
the identity of pancreatic progenitor cells.
 The human genome contains the instructions 
to generate all the cell types that are formed during 
embryonic development. Building such complex systems 
is in part possible because the transcription of different sets 
of genes is sequentially activated or repressed generating 
cell-specific combinatorial profiles. Enhancers are one 
class of non-coding cis-regulatory sequences that control 
the transcription of genes. Also, the specific temporal and 
spatial regulatory activity of each enhancer is defined by 
clusters of transcription factors (TFs) that are bound to 
these sequences. Therefore, understanding the identity of 
pancreatic progenitor cells requires the identification of 
these regulatory sequences and the TFs that bind to them.
Our recent work published in Nature Cell Biology 
characterized the identity of human pancreatic progenitor 
cells [3]. For this purpose, we used human fetal pancreas, 
which was dissected from embryos at an early stage of 
gestation (~ 6 weeks), as well as pancreatic progenitor 
cells derived in vitro from human embryonic stem cells 
(hESC), that matched the developmental stage of cells in 
the fetal pancreas. We took advantage of high throughput 
sequencing techniques to identify genes that are selectively 
expressed in both samples and to produce a map of the 
genomic sequences that act as enhancers in the human 
embryonic pancreas. The results showed that pancreatic 
progenitor cells derived in vitro effectively recapitulate 
the main properties of the transcriptional program of the 
fetal progenitor cells, validating the in vitro system. In 
addition, further analysis of the regulatory regions active 
in pancreatic progenitor cells uncovered how genes can 
be transcriptionally regulated at this specific cell stage. 
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Figure 1: The role of YAP and TEAD in the activation of enhancers of pancreatic multipotent progenitor cells and 
their possible contribution to human pancreatic diseases. Cis-regulatory modules (CRMs) are regions within the enhancers that 
show extensive TF co-binding.
Oncotarget2www.impactjournals.com/oncotarget
We report that these regulatory regions are recognized 
by several TFs that have been previously described to be 
mutated in patients with congenital defects in pancreas 
development. Additionally, we found that the majority 
of these enhancers are recognized by TEAD proteins and 
its co-activator factor YAP, two important effectors of the 
Hippo signaling pathway [4]. Two recent reports have 
shown that pancreas-specific disruption of the upstream 
Hippo kinases Mst1/2 leads to acinar differentiation 
defects and changes in pancreas architecture [5, 6]. These 
reports, however, do not address whether Hippo signaling 
or TEAD are important for pancreatic progenitors. The 
results reported in our recent work show that TEAD 
and YAP play a key role in the identity of pancreatic 
progenitor cells. This was confirmed by functional studies, 
performed in progenitors derived from hESC, pancreatic 
bud explants from mouse embryos, and zebrafish, which 
showed that TEAD and YAP not only play a key role in 
the activation of these regulatory regions, but also control 
cell proliferation in embryonic pancreatic progenitor 
cells. We end up with a model for early pancreas 
development in which specific non-coding regions of the 
genome are exquisitely defined by co-binding of several 
pancreas-specific TFs, which are timely co-expressed at 
the progenitor cell stage (green shapes in Figure 1). A 
subset of such regions is also bound by TEAD proteins 
(light blue in Figure 1), and this combination of factors 
somehow marks them as “poised” enhancers, awaiting 
timely enhancer activation. Proper activation is provided 
by YAP nuclear translocation and binding to TEAD-
targeted enhancers (red circles in Figure 1), thus leading 
to increased expression of target genes. Given that the 
control of YAP intracellular localization is mainly driven 
by the Hippo kinase cascade (orange shapes in Figure 1), 
this would confer a means for pancreatic progenitors to 
integrate extracellular signaling cues to control a timely 
cell differentiation program. The identified role for TEAD 
and YAP in this process opens up new research avenues 
towards disease development in humans. YAP has been 
described as an oncogene involved in several types of 
cancer, including pancreatic ductal adenocarcinoma [4]. 
Our results suggest that the reactivation of the pancreatic 
embryonic program in adult pancreatic cells could 
contribute to dedifferentiation and uncontrolled growth 
during pancreatic carcinogenesis. In this context, YAP, 
TEAD, or their pancreatic-specific downstream genes 
could be used as targets of new anti-cancer drugs. On the 
other hand, the regulatory program described in our work 
could be potentially exploited to control the growth and 
differentiation of in vitro derived pancreatic beta cells, 
aiming for treatment of diabetic patients in which these 
cells have been destroyed. Diabetes can also result from the 
impairment of proper beta-cell embryonic development, 
which has been classically attributed as the result of 
coding mutations in key pancreatic developmental genes. 
Using a preliminary version of the regulatory regions 
that we recently reported, the groups of  Prof. Ferrer and 
Prof. Hattersley have shown that, in addition to coding 
mutations, regulatory mutations might also cause severe 
developmental defects of the pancreas, such as pancreatic 
agenesis [7]. Therefore, the atlas of regulatory elements 
of pancreatic progenitor cells described in our work could 
be used to define genomic hotspots of mutations with the 
potential to impair proper pancreas development. Indeed, 
with current technologies allowing the sequencing of a 
patient’s genome at an affordable cost, this will become a 
possibility in the near future.
In summary, we have now unveiled a novel role for 
YAP and TEAD proteins in the control of gene expression 
during pancreas development. These findings now turn the 
spotlight on YAP and the Hippo pathway, placing them 
at the crossroads of pancreas formation. Special attention 
should be directed from here on to check the expression 
or activity of YAP as well as kinases involved in Hippo 
signaling, since these might underlie defects in pancreas 
development resulting from non-coding genetic mutations 
or adverse environmental cues. A new path has been 
opened ahead and we now count with an epigenomic road 
map to evaluate causes of human pancreas disease that 
could be linked with its developmental process.
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